



Dated: August 23, 2023

To,

National Stock Exchange of India Ltd,  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

**Company Symbol: Dentalkart, ISIN: INE0N5801013**

**Sub: Outcome of the Board Meeting**

Respected Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), we hereby inform you that meeting of the Board of Directors of Vasa Denticity Limited ("Company"), was held through Video-Conference today i.e. August 23, 2023 and *inter-alia* approved the following:

1. Acquisition of 100% equity shares of Waldent Innovations Private Limited ("Waldent"), a Group Company and make it a wholly owned subsidiary, at a consideration of Rs. 10,00,000 by acquiring 10,000 shares (FV Rs. 10 /- each) of the Waldent at the price of Rs. 100 per share.

The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as **Annexure I**

2. Approval of Employees Stock Option Scheme– 2023 ("VASA ESOS, 2023")

In order to reward the Employees for their association, dedication and contribution towards the goals of the Company and to retain key talents working with the Company, the Board in its meeting held today has approved Employees Stock Option Scheme – 2023 ("VASA ESOS, 2023"), subject to the approval of the members of the Company.

The Board Meeting commenced at 1:28 P.M. and concluded at 1:40 P.M.

Further, pursuant to Regulation 30(8) of the Listing Regulations the enclosed disclosures will be made available on the Company's website at: [www.dentalkart.com](http://www.dentalkart.com).

You are requested to take the above information on your records and disseminate the same on your website. Thanking you,

Yours sincerely,  
VASA Denticity Limited

*(Formerly known as VASA Denticity Private Limited)*

VIKAS  
AGARWAL  
Digitally signed by  
VIKAS AGARWAL  
Date: 2023.08.23  
13:44:23 +05'30'

Vikas Agarwal  
Managing Director  
DIN: 07487686



### Annexure I

Disclosure under sub-para (1) [i.e Acquisition(s)] of Para A of Part A of Schedule III to the Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

| Sr. No. | Particulars                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.      | Name of the Target Entity including brief details such as size, turnover etc.;                                                                                                                                                                                          | <b>Name:</b> Waldent Innovations Private Limited ("WIPL"), engaged in the business of trading of dental equipment, consumables and instruments.<br><br><b>Turnover:</b> INR 3,79,09,634 (For the year ended 31.03.2023).                                                                                                                                                                         |
| 2.      | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"; | <p>The acquisition was duly approved by the Audit Committee and the Board of Directors on August 23, 2023.</p> <p>The acquisition of WIPL is a related party transaction as Dr. Vikas Agarwal and Mr. Sandeep Aggarwal, Promoters and Directors of Dentalkart are also promoters and Directors of WIPL (Target Company).</p> <p>The acquisition of WIPL is being done at arm's length basis.</p> |
| 3.      | Industry to which the entity being acquired belongs.                                                                                                                                                                                                                    | WIPL is engaged in the business of trading of dental equipment, consumables and instruments.                                                                                                                                                                                                                                                                                                     |
| 4.      | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).                                                                   | The acquisition will enable Dentalkart to grow and expand its business as WIPL is in the same industry type of Dentalkart and by acquiring WIPL, Dentalkart will also have control over technology, innovations and intellectual properties of WIPL.                                                                                                                                             |
| 5.      | Brief details of any governmental or regulatory approvals required for the acquisition;                                                                                                                                                                                 | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                  |
| 6.      | Indicative time period for completion of the acquisition;                                                                                                                                                                                                               | Equity stake of WIPL to be completed within 3 Months from the date of approval of Board and Audit Committee.                                                                                                                                                                                                                                                                                     |



| 7.             | Nature of consideration - whether cash consideration or share swap and details of the same;                                                                                                                                                               | Consideration in Cash                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                |           |          |         |           |             |         |           |             |         |           |             |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-----------|----------|---------|-----------|-------------|---------|-----------|-------------|---------|-----------|-------------|
| 8.             | Cost of acquisition or the price at which the shares are acquired                                                                                                                                                                                         | Aggregate consideration of INR 10,00,000/- is being paid by the Company for acquiring 10,000 equity shares of WIPL at INR 100 each which constitutes 100% shareholding of WIPL.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                |           |          |         |           |             |         |           |             |         |           |             |
| 9.             | Percentage of shareholding / control acquired and/or number of shares acquired;                                                                                                                                                                           | Dentalkart is acquiring equity shares equivalent to 100% of the issued and subscribed capital of WIPL from its promotes/shareholders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                |           |          |         |           |             |         |           |             |         |           |             |
| 10.            | Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief). | <p>WIPL was founded by two young entrepreneurs Dr. Vikas Agarwal and Mr. Sandeep Agarwal and incorporated under Companies Act, 2013 having its Registered office at Khasra No. 714, Village P.O. Chattarpur, New Delhi- 110074.</p> <p>Paid-up Share Capital of WIPL is Rs. 1,00,000 (INR One Lakh only) held by its Shareholders cum Directors viz Dr Vikas Agarwal and Mr. Sandeep Aggarwal in equal proportion.</p> <p>WIPL is engaged in the B2B trading of dental equipment, consumables and instruments.</p> <p>The turnover and Networth of WIPL for the last three financial years are stated below:</p> <table> <tr> <th>Financial Year</th><th>Net worth</th><th>Turnover</th></tr> <tr> <td>2022-23</td><td>10,01,900</td><td>3,79,09,634</td></tr> <tr> <td>2021-22</td><td>11,87,275</td><td>6,00,93,779</td></tr> <tr> <td>2020-21</td><td>10,19,243</td><td>5,06,20,397</td></tr> </table> | Financial Year | Net worth | Turnover | 2022-23 | 10,01,900 | 3,79,09,634 | 2021-22 | 11,87,275 | 6,00,93,779 | 2020-21 | 10,19,243 | 5,06,20,397 |
| Financial Year | Net worth                                                                                                                                                                                                                                                 | Turnover                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                |           |          |         |           |             |         |           |             |         |           |             |
| 2022-23        | 10,01,900                                                                                                                                                                                                                                                 | 3,79,09,634                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                |           |          |         |           |             |         |           |             |         |           |             |
| 2021-22        | 11,87,275                                                                                                                                                                                                                                                 | 6,00,93,779                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                |           |          |         |           |             |         |           |             |         |           |             |
| 2020-21        | 10,19,243                                                                                                                                                                                                                                                 | 5,06,20,397                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                |           |          |         |           |             |         |           |             |         |           |             |

